Oragenics announces plans to conduct public offering of common stock

Public sale to be conducted on a firm-commitment basis, company says

By Devika Patel

Knoxville, Tenn., Nov. 14 - Oragenics, Inc. said it will price a public sale of common stock. Griffin Securities, Inc. is the sole underwriter.

The offering will be conducted on a firm-commitment basis.

Proceeds will be used for development of the company's lantibiotics program and general corporate and working capital purposes.

Oragenics is a Tampa, Fla.-based biopharmaceutical company focused on novel antibiotics for infectious disease and probiotics for oral health for humans and pets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.